Skip to main content
. 2019 Nov 25;8(2):76–81. doi: 10.1016/j.ijpam.2019.11.005

Table 2.

Univariate analysis comparing neonates with any IVH, mild IVH, and severe IVH and controls (no IVH).

Parameters Any IVH group (n = 108) Control group (n = 108) P value Mild IVH group (n = 56) Control group (n = 56) P value Severe IVH group (n = 52) Control group (n = 52) P value
Antenatal steroid (≥1 dose) 49 (45.4) 69 (63.9) .007* 34 (60.7) 33 (58.9) .847 15 (28.8) 36 (69.2) <.001*
Cesarean section 53 (49.1) 60 (55.6) .341 30 (53.6) 34 (60.7) .445 23 (44.2) 26 (50) .556
PIH 21 (19.4) 27 (25) .327 14 (25) 16 (28.6) .670 7 (13.5) 11 (21.2) .303
GDM 8 (7.4) 9 (8.3) .163 7 (5.4) 7 (12.5) .197 1 (1.9) 2 (3.8) .566
Male 58 (53.7) 53 (49.1) .496 32 (57.1) 27 (48.2) .345 26 (50) 26 (50) 1
RDS surfactant use 80 (74.1) 71 (65.7) .183 36 (64.3) 31 (55.4) .336 44 (84.6) 40 (76.9) .322
Invasive respiratory support 89 (75) 79 (84.3) .104 43 (76.8) 36 (64.3) .149 46 (88.5) 43 (82.7) .405
Pneumothorax 11 (10.2) 3 (2.8) .038* 6 (10.7) 0 (0) .999 5 (9.6) 3 (5.8) .360
Pulmonary hemorrhage 17 (15.7) 5 (4.6) .011* 4 (7.1) 1 (1.8) .204 13 (25) 4 (7.7) .023*
Inotropes 49 (45.4) 32 (29.6) .018* 17 (30.4) 11 (19.6) .193 32 (61.5) 21 (40.4) .032*
Hydrocortisone 34 (31.5) 19 (17.6) .019* 7 (12.5) 9 (16.1) 0.590 27 (51.9) 10 (19.2) .001*
PDA 69 (63.9) 53 (49.1) .029* 29 (51.8) 27 (48.2) .706 40 (76.9) 26 (50 .005*
PDA (treated with medication) 15 (13.9) 14 (13) .842 4 (7.1) 6 (10.7) .510 11 (21.2) 8 (15.4) .448
Nitric oxide 1 (0.93) 0 1 0 0 .849 1 (1.9) 0 1

*P < .05.

IVH: Intraventricular hemorrhage; PIH: Pregnancy-induced hypertension; GDM: Gestational diabetes mellitus; RDS: Respiratory distress syndrome; PDA: Patent ductus arteriosus.